
Cetrotide250 mcg/vi
Janata Traders
Cetrorelix Acetate is a gonadotropin-releasing hormone (GnRH) antagonist indicated for the following use: Established/FDA-approved use: Prevention of a premature luteinizing hormone (LH) surge in…
Cetrorelix Acetate is a gonadotropin-releasing hormone (GnRH) antagonist indicated for the following use:
Cetrorelix Acetate is always used as an adjunct to, and concurrently with, exogenous gonadotropin therapy (e.g., follicle-stimulating hormone preparations) during a supervised ovarian stimulation cycle; it is not used as a standalone fertility treatment. There are no other well-established or guideline-supported indications outside assisted reproduction, and off-label use in other endocrine conditions (e.g., experimental use in endometriosis or uterine fibroids) is not routine and is not recommended outside a research setting.
Cetrorelix Acetate is given by subcutaneous injection, preferably into the lower abdomen, and is used together with gonadotropin therapy under specialist supervision. Two regimens are used:
| Regimen | Dose | Timing |
|---|---|---|
| Multiple-dose (0.25 mg) regimen | 0.25 mg once daily | Starting on stimulation day 5 or 6 (morning or evening, per protocol) and continuing daily until the day of hCG administration (day of triggering ovulation) |
| Single-dose (3 mg) regimen | One 3 mg dose | Given once on stimulation day 7; if stimulation continues beyond 4 days after this dose, 0.25 mg once daily is added until the hCG trigger day |
The reconstituted solution should be injected immediately by slow subcutaneous injection, with rotation of injection sites to reduce local skin reactions. Cetrorelix Acetate must be administered under the supervision of a physician experienced in fertility treatment; see Reconstitution for preparation instructions.
The most commonly reported side effects of Cetrorelix Acetate include:
Less common but clinically important effects include hypersensitivity reactions, up to and including anaphylaxis (see Precautions and Warnings), and ovarian hyperstimulation syndrome (OHSS), which is a recognized risk of the overall gonadotropin-stimulated ART cycle rather than an effect of Cetrorelix Acetate itself (see Precautions and Warnings).
Cetrorelix Acetate is contraindicated in the following situations:
Severe renal impairment has not been adequately studied and warrants caution rather than absolute avoidance; see Precautions and Warnings and Use in Special Populations.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.